Dr. Lee Kaplan, Director at Dartmouth Health’s Weight and Wellness Center, points to the myostatin/activin pathway as a promising target.

Obesity care is evolving – and so is the science behind it. Dr. Lee Kaplan, Director at Dartmouth Health‘s Weight and Wellness Center, points to the myostatin/activin pathway as a promising target. Vial’s INHBE is at the forefront of this research, with potential to enhance fat loss while preserving lean mass, opening new possibilities for patients and clinicians alike.

View on Linkedin

More Resources

Press Releases

The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next‑Generation Obesity Therapy

Videos

Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research on the next breakthroughs in obesity treatment.

Videos

Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.

Connect with us.

Interested in receiving a proposal from Vial? Leave us a message and some of your contact info and we’ll be in touch with you shortly.

Facebook

This field is for validation purposes and should be left unchanged.

Name(Required)

Work email(Required)

Phone

Company(Required)

Which best describes you?(Required)

Message

By submitting, you are agreeing to our terms and privacy policy